{
  "openalex_id": "W2394806078",
  "doi": "https://doi.org/10.1158/1557-3265.ovca15-a11",
  "title": "Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.",
  "abstract": "Abstract Background: PARP inhibitors (PARPi) are synthetically lethal to tumor cells with homologous recombination deficiency (HRD). HRD can result from deleterious BRCA1/2 mutations (BRCAmut) or other mechanisms that have not been fully elucidated. Regardless of mechanism, HRD leads to a common phenotype of genome-wide loss of heterozygosity (LOH). It has been hypothesized that this genomic phenotype can be used to identify BRCA wild-type (BRCAwt) HRD tumors likely sensitive to PARPi. Using comprehensive next generation sequencing (NGS)-based tumor genomic profiling, we developed an HRD assay for potential use as a companion diagnostic for rucaparib in high-grade ovarian cancer (HGOC) by combining tumor BRCA1/2 status and quantification of genomic LOH. Methods: In the phase 2 study ARIEL2 Part 1 (NCT01891344), pre-treatment screening biopsies and archival formalin-fixed paraffin embedded tumor specimens were profiled using Foundation Medicine's NGS-based HRD assay, which detects all classes of genomic alterations, including base substitutions, insertions/deletions, and homozygous deletions in BRCA1/2. Genomic LOH was assessed by sequencing &amp;gt;3,500 evenly-distributed single nucleotide polymorphisms across the genome and quantifying the extent of genomic LOH. A pre-specified genomic LOH cutoff was determined using publicly available SNP array data of ovarian tumors to predict platinum sensitivity as a surrogate marker for PARPi sensitivity. Response was assessed by RECIST v1.1 and GCIG CA-125 response criteria. Results: As of July 1 2015, 195 archival tumor and 152 screening biopsy samples (142 matched pairs) from 206 HGOC patients enrolled (204 patients treated) in ARIEL2 Part 1 were successfully profiled using the NGS-based HRD assay. Some screening biopsies were not suitable for successful NGS-based HRD assessment primarily because of insufficient tumor nuclei or inadequate tumor volume. Most matched pairs of archival and pre-trial screening samples exhibited similar genomic LOH profiles (r=0.86); however, 14% of screening samples had higher genomic LOH compared with archival samples collected more than one year earlier. All BRCA1/2 germline and somatic mutated tumors had high genomic LOH in the screening samples. Receiver operating characteristic analysis of genomic LOH showed utility in identifying RECIST/CA-125 responders to rucaparib (AUC=0.72, p&amp;lt;1e-4), with slightly better predictive utility using screening samples compared to archival samples (AUC=0.72 vs 0.69). Using the pre-specified genomic LOH cutoff, high genomic LOH tumors were detected in 54% of evaluable BRCAwt patients; significantly different overall response rates were found in patients with high vs low genomic LOH tumors (48% vs 26%; chi-square p=0.0074). Conclusions: We developed an NGS-based HRD assay that assesses tumor BRCA1/2 and genomic LOH to prospectively identify HGOC patients who may benefit from rucaparib treatment. The optimized NGS-based HRD assay will be prospectively tested in the ongoing portion of the phase 2 study (ARIEL2 Part 2, NCT01891344) and a phase 3 maintenance study (ARIEL3, NCT01968213) that will investigate rucaparib in HGOC. Citation Format: Iain A. McNeish, Kevin K. Lin, James X. Sun, Sandra Goble, Amit Oza, Robert L. Coleman, Clare L. Scott, Gottfried Konecny, Anna V. Tinker, David M. O'Malley, Rebecca Kristeleit, Ling Ma, James D. Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano, Roman Yelensky, Mitch Raponi, Elizabeth Swisher. NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A11.",
  "authors": [
    {
      "display_name": "Iain A. McNeish",
      "id": "A5089242165",
      "orcid": "https://orcid.org/0000-0002-9387-7586",
      "institutions": [
        {
          "id": "I7882870",
          "display_name": "University of Glasgow",
          "country_code": "GB",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Iain A. McNeish"
    },
    {
      "display_name": "Kevin Lin",
      "id": "A5074764224",
      "orcid": "https://orcid.org/0000-0002-1236-9847",
      "institutions": [
        {
          "id": "I4210151488",
          "display_name": "Clovis Oncology (United States)",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Kevin K. Lin"
    },
    {
      "display_name": "James Sun",
      "id": "A5023204946",
      "orcid": "https://orcid.org/0000-0002-9915-6974",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "James X. Sun"
    },
    {
      "display_name": "Sandra Goble",
      "id": "A5111964118",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210151488",
          "display_name": "Clovis Oncology (United States)",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Sandra Goble"
    },
    {
      "display_name": "Amit M. Oza",
      "id": "A5072712459",
      "orcid": "https://orcid.org/0000-0002-9510-8641",
      "institutions": [
        {
          "id": "I2802654988",
          "display_name": "Princess Margaret Cancer Centre",
          "country_code": "CA",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Amit Oza"
    },
    {
      "display_name": "Robert L. Coleman",
      "id": "A5009234043",
      "orcid": "https://orcid.org/0000-0001-9343-8754",
      "institutions": [
        {
          "id": "I1343551460",
          "display_name": "The University of Texas MD Anderson Cancer Center",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Robert L. Coleman"
    },
    {
      "display_name": "Clare L. Scott",
      "id": "A5085126287",
      "orcid": "https://orcid.org/0000-0002-3689-5956",
      "institutions": [
        {
          "id": "I196021976",
          "display_name": "Walter and Eliza Hall Institute of Medical Research",
          "country_code": "AU",
          "type": "nonprofit"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Clare L. Scott"
    },
    {
      "display_name": "Gottfried E. Konecny",
      "id": "A5062837404",
      "orcid": "https://orcid.org/0000-0001-6083-657X",
      "institutions": [
        {
          "id": "I1317197149",
          "display_name": "APLA Health",
          "country_code": "US",
          "type": "nonprofit"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Gottfried Konecny"
    },
    {
      "display_name": "Anna V. Tinker",
      "id": "A5078857320",
      "orcid": "https://orcid.org/0000-0002-1190-7746",
      "institutions": [
        {
          "id": "I1289530486",
          "display_name": "BC Cancer Agency",
          "country_code": "CA",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Anna V. Tinker"
    },
    {
      "display_name": "David M. O’Malley",
      "id": "A5021359849",
      "orcid": "https://orcid.org/0000-0002-2828-0177",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "David M. O'Malley"
    },
    {
      "display_name": "Rebecca Kristeleit",
      "id": "A5088144652",
      "orcid": "https://orcid.org/0000-0003-3825-1326",
      "institutions": [
        {
          "id": "I45129253",
          "display_name": "University College London",
          "country_code": "GB",
          "type": "funder"
        },
        {
          "id": "I4210144746",
          "display_name": "The London College",
          "country_code": "GB",
          "type": "education"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Rebecca Kristeleit"
    },
    {
      "display_name": "Ling Ma",
      "id": "A5101562260",
      "orcid": "https://orcid.org/0000-0003-2638-3065",
      "institutions": [
        {
          "id": "I4210140702",
          "display_name": "Rocky Mountain Cancer Centers",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Ling Ma"
    },
    {
      "display_name": "James D. Brenton",
      "id": "A5051525398",
      "orcid": "https://orcid.org/0000-0002-5738-6683",
      "institutions": [
        {
          "id": "I2801316944",
          "display_name": "Cancer Research UK",
          "country_code": "GB",
          "type": "nonprofit"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "James D. Brenton"
    },
    {
      "display_name": "Katherine M. Bell‐McGuinn",
      "id": "A5071199136",
      "orcid": null,
      "institutions": [
        {
          "id": "I39965400",
          "display_name": "Kettering University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Katherine Bell-McGuinn"
    },
    {
      "display_name": "Ana Oaknin",
      "id": "A5067053417",
      "orcid": "https://orcid.org/0000-0002-3592-7194",
      "institutions": [
        {
          "id": "I4387155398",
          "display_name": "Vall d'Hebron Institute of Oncology",
          "country_code": null,
          "type": "healthcare"
        },
        {
          "id": "I4210127641",
          "display_name": "Vall d'Hebron Hospital Universitari",
          "country_code": "ES",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Ana Oaknin"
    },
    {
      "display_name": "Alexandra Léary",
      "id": "A5025155327",
      "orcid": "https://orcid.org/0000-0002-2043-2244",
      "institutions": [
        {
          "id": "I2801843802",
          "display_name": "Institut Gustave Roussy",
          "country_code": "FR",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Alexandra Leary"
    },
    {
      "display_name": "Elaina Mann",
      "id": "A5109602101",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210151488",
          "display_name": "Clovis Oncology (United States)",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Elaina Mann"
    },
    {
      "display_name": "Heidi Giordano",
      "id": "A5019014876",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210151488",
          "display_name": "Clovis Oncology (United States)",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Heidi Giordano"
    },
    {
      "display_name": "Roman Yelensky",
      "id": "A5079433880",
      "orcid": "https://orcid.org/0000-0002-5356-0111",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Roman Yelensky"
    },
    {
      "display_name": "Mitch Raponi",
      "id": "A5018531947",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210151488",
          "display_name": "Clovis Oncology (United States)",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Mitch Raponi"
    },
    {
      "display_name": "Elizabeth M. Swisher",
      "id": "A5084420374",
      "orcid": "https://orcid.org/0000-0003-2331-0434",
      "institutions": [
        {
          "id": "I201448701",
          "display_name": "University of Washington",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Elizabeth Swisher"
    }
  ],
  "publication_year": 2016,
  "publication_date": "2016-01-15",
  "type": "article",
  "cited_by_count": 0,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S183149254",
    "display_name": "Clinical Cancer Research",
    "issn_l": "1078-0432",
    "issn": [
      "1078-0432",
      "1557-3265"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320273"
  },
  "volume": "22",
  "issue": "2_Supplement",
  "first_page": "A11",
  "last_page": "A11",
  "open_access": {
    "is_oa": false,
    "oa_status": "closed",
    "oa_url": null,
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C143589142",
      "display_name": "Loss of heterozygosity",
      "level": 4,
      "score": 0.64838046
    },
    {
      "id": "C2779138821",
      "display_name": "PARP inhibitor",
      "level": 5,
      "score": 0.61700344
    },
    {
      "id": "C2780427987",
      "display_name": "Ovarian cancer",
      "level": 3,
      "score": 0.5769468
    },
    {
      "id": "C2779962180",
      "display_name": "Olaparib",
      "level": 5,
      "score": 0.5327943
    },
    {
      "id": "C86803240",
      "display_name": "Biology",
      "level": 0,
      "score": 0.5147136
    },
    {
      "id": "C502942594",
      "display_name": "Cancer research",
      "level": 1,
      "score": 0.49729684
    },
    {
      "id": "C2778502085",
      "display_name": "Synthetic lethality",
      "level": 4,
      "score": 0.45188555
    },
    {
      "id": "C153209595",
      "display_name": "Single-nucleotide polymorphism",
      "level": 4,
      "score": 0.41079968
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.4069124
    },
    {
      "id": "C54355233",
      "display_name": "Genetics",
      "level": 1,
      "score": 0.34184015
    },
    {
      "id": "C135763542",
      "display_name": "Genotype",
      "level": 3,
      "score": 0.282656
    },
    {
      "id": "C134935766",
      "display_name": "DNA repair",
      "level": 3,
      "score": 0.22245458
    },
    {
      "id": "C104317684",
      "display_name": "Gene",
      "level": 2,
      "score": 0.2143848
    },
    {
      "id": "C180754005",
      "display_name": "Allele",
      "level": 3,
      "score": 0.13873696
    },
    {
      "id": "C182979987",
      "display_name": "Poly ADP ribose polymerase",
      "level": 4,
      "score": 0.11147049
    },
    {
      "id": "C82381507",
      "display_name": "Polymerase",
      "level": 3,
      "score": 0.0
    }
  ],
  "topics": [
    {
      "id": "T11914",
      "display_name": "PARP inhibition in cancer therapy",
      "score": 0.9913
    },
    {
      "id": "T11287",
      "display_name": "Cancer Genomics and Diagnostics",
      "score": 0.9768
    },
    {
      "id": "T11369",
      "display_name": "Genetic factors in colorectal cancer",
      "score": 0.9546
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1158/1557-3265.ovca15-a11",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T15:21:25.664666",
  "source_database": "OpenAlex"
}